BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Abell 1201 BCG than expected from the usual scaling relations between black holes and host galaxies. However, alternative methods of modelling the stellar velocity dispersion maps reveals an ambiguity between the UMBH mass and the dark halo profile. In solutions where the UMBH is more massive, the dark matter is more cuspy. In solutions where the UMBH is smaller or absent, the dark matter is more cored. The dark halo's ellipticity and the mass-to-light ratio of stars also enter the ambiguity. Thus, if the standard computational models are robust, then Abell 1201 BCG presents a dilemma and a challenge to either the conventional